SCHEMBL1572762

SCHEMBL1572762

COc1c(C)c(C(=O)c2ccc(N)c(C(=O)O)c2)n2cc(OCc3ccccc3)ccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRD5A2 P31213 3/20 0.39
▸ NR4A1 P22736 1/20 0.39
▸ NR4A2 P43354 1/20 0.39
▸ NR4A3 Q92570 1/20 0.39
▸ LTB4R Q15722 2/20 0.39
▸ LTB4R2 Q9NPC1 2/20 0.39
▸ ALKBH1 Q13686 1/20 0.39
▸ MAOB P27338 1/20 0.38
▸ PARP10 Q53GL7 1/20 0.38
▸ PTGES O14684 1/20 0.38
▸ LNPEP Q9UIQ6 3/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ NFKB1 P19838 1/20 0.37
▸ NFKB2 Q00653 1/20 0.37
▸ RELA Q04206 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4509609 0.93 LNPEP (0.42) SRD5A2LTB4RLTB4R2MAOBPARP10
SCHEMBL3947583 0.88 ALDH1A1 (0.36) RAB9AKDM4EALDH1A1KMT2A
SCHEMBL1573088 0.87 RARB (0.34) RAB9AKDM4EALDH1A1KMT2A
SCHEMBL1573232 0.87 ALDH1A1 (0.33) RAB9ASMN1; SMN2TP53KDM4EALDH1A1
SCHEMBL1573145 0.87 RARB (0.34) RAB9AKDM4EALDH1A1KMT2A
SCHEMBL1573306 0.84 POLB (0.36) POLBPKMRXFP1KDM4EMEN1
SCHEMBL3944692 0.82 L3MBTL1 (0.40) SRD5A2NR4A1NR4A2NR4A3MAOB
SCHEMBL4500669 0.81 LMNA (0.34) SMN1; SMN2KDM4EMEN1ALDH1A1KMT2A
SCHEMBL1572836 0.81 RXRA (0.41) RAB9ASMN1; SMN2NPC1MRGPRX4KDM4E
SCHEMBL145931 0.81 HTT (0.45) SMN1; SMN2MEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9120819-B2 FGF-receptor agonist dimeric compounds SANOFI (FR) 2015-09-01 — — US disclosed
EP-2018165-B1 FGF-PECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI AVENTIS (FR) 2011-04-13 — — EP disclosed
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI-AVENTIS (FR) 2009-03-12 — — US disclosed
EP-2018165-A1 FGF-PECEPTOR AGONIST DIMERIC COMPOUNDS Sanofi-Aventis (FR) 2009-01-28 — — EP disclosed
WO-2007080325-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI-AVENTIS (FR) 2007-07-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS FGF2, FGFR1, FGF1 SRD5A2 2616/4885NR4A1 181/4885NR4A2 264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback